| case report | Q2782326 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Peter Heeringa | Q57559944 |
| P2093 | author name string | Elisabeth Brouwer | |
| Wayel H Abdulahad | |||
| Annemieke M H Boots | |||
| G A P Hospers | |||
| Rebeca Hid Cadena | |||
| T T Wind | |||
| P2860 | cites work | Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells. | Q51048336 |
| Approvals in 2016: the march of the checkpoint inhibitors. | Q52788400 | ||
| Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. | Q54534749 | ||
| Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4 | Q56897001 | ||
| PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer | Q56898302 | ||
| CTLA-4 upregulation during aging | Q56904354 | ||
| Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors | Q56909582 | ||
| IL-18 Induces PD-1-Dependent Immunosuppression in Cancer | Q57556330 | ||
| Healthy Aging and Latent Infection with CMV Lead to Distinct Changes in CD8+ and CD4+ T-Cell Subsets in the Elderly | Q58444239 | ||
| Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis | Q58621638 | ||
| Wegener's granulomatosis in the elderly | Q69609364 | ||
| Make or break for costimulatory blockers | Q75382026 | ||
| Polymyalgia rheumatica and giant-cell arteritis | Q81668995 | ||
| Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition | Q89166650 | ||
| Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation | Q24311763 | ||
| CD28/B7 system of T cell costimulation | Q24313544 | ||
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| The PD-1 pathway in tolerance and autoimmunity | Q24633549 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| Tumor-specific Th17-polarized cells eradicate large established melanoma | Q24648032 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | Q27853339 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy | Q28066199 | ||
| The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma | Q28088496 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells | Q28243975 | ||
| CD28 and CTLA-4 coreceptor expression and signal transduction | Q28244243 | ||
| Reversal of the TCR stop signal by CTLA-4 | Q28259985 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides | Q28276589 | ||
| Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Epidemiology of systemic vasculitis: changing incidence or definition? | Q50609774 | ||
| Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. | Q50960736 | ||
| A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application | Q38163290 | ||
| Do inhibitory immune receptors play a role in the etiology of autoimmune disease? | Q38170897 | ||
| The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge | Q38677347 | ||
| Is autoimmunity the Achilles' heel of cancer immunotherapy? | Q38687375 | ||
| Immune checkpoint inhibitors and elderly people: A review | Q38688111 | ||
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review | Q38696141 | ||
| VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer | Q38710357 | ||
| Coinhibitory Pathways in Immunotherapy for Cancer | Q38755150 | ||
| Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. | Q38916367 | ||
| Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? | Q38931441 | ||
| Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer | Q39085984 | ||
| Recent advances in our understanding of giant cell arteritis pathogenesis | Q39341667 | ||
| Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules. | Q39453094 | ||
| Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 | ||
| Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities | Q40041736 | ||
| The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. | Q40067370 | ||
| A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis | Q40353912 | ||
| When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes | Q40602726 | ||
| The biology of replicative senescence | Q41583618 | ||
| Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy | Q42085981 | ||
| Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity | Q42204050 | ||
| Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. | Q42321741 | ||
| Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection | Q42945184 | ||
| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells | Q43448621 | ||
| CTLA-4-Ig regulates tryptophan catabolism in vivo. | Q44170968 | ||
| T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. | Q44384732 | ||
| Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab | Q44588912 | ||
| Modulation of tryptophan catabolism by regulatory T cells. | Q44632333 | ||
| Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade | Q47958949 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Q30251438 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| CD28(-) T cells: their role in the age-associated decline of immune function | Q33572405 | ||
| Oncology meets immunology: the cancer-immunity cycle | Q34037625 | ||
| Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection | Q34093225 | ||
| Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
| Age-related changes in lymphocyte development and function | Q34293466 | ||
| T cells in vascular inflammatory diseases | Q34336323 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. | Q34808086 | ||
| IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis | Q34847819 | ||
| Immune checkpoint receptors in regulating immune reactivity in rheumatic disease | Q34897654 | ||
| Bevacizumab plus ipilimumab in patients with metastatic melanoma | Q35012765 | ||
| Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy | Q35237202 | ||
| Role of persistent CMV infection in configuring T cell immunity in the elderly | Q35696950 | ||
| T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection | Q35753066 | ||
| Pathophysiology of ageing, longevity and age related diseases | Q35985777 | ||
| Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients | Q36020800 | ||
| Tissue expression of PD-L1 mediates peripheral T cell tolerance. | Q36228541 | ||
| B70 antigen is a second ligand for CTLA-4 and CD28 | Q36697598 | ||
| T(H)-17 cells in the circle of immunity and autoimmunity | Q36765453 | ||
| CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients | Q36937124 | ||
| CTLA4 blockade increases Th17 cells in patients with metastatic melanoma | Q37229358 | ||
| PD-1 signaling in primary T cells | Q37474915 | ||
| Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database | Q37605666 | ||
| Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer | Q37616503 | ||
| Pathogenic features of CD4+CD28- T cells in immune disorders. | Q38025492 | ||
| Chronic autoimmune-mediated inflammation: a senescent immune response to injury | Q38063635 | ||
| Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis | Q38076499 | ||
| The gracefully aging immune system | Q38107139 | ||
| The influence of ageing on the development and management of rheumatoid arthritis | Q38115131 | ||
| Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. | Q38117980 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | melanoma | Q180614 |
| vasculitis | Q644318 | ||
| autoimmune disease | Q8084905 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 315 | |
| P577 | publication date | 2018-02-22 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Checks and Balances in Autoimmune Vasculitis | |
| P478 | volume | 9 |
| Q90030540 | Cardiovascular immune-related adverse events: Evaluation, diagnosis and management |
| Q93158326 | Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study |
| Q91801539 | Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy |
| Q92404929 | Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA |
| Q92363011 | Novel Delivery Systems for Checkpoint Inhibitors |
| Q93020504 | Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.